Study of ICP-105 in Solid Tumors Patients

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 21, 2018

Primary Completion Date

December 14, 2020

Study Completion Date

March 1, 2021

Conditions

Solid Tumor

Interventions

DRUG

ICP-105

25mg, 100mg capsule

Trial Locations (1)

Shanghai East Hospital, Shanghai

All Listed Sponsors

lead

Beijing InnoCare Pharma Tech Co., Ltd.

INDUSTRY

NCT03642834 - Study of ICP-105 in Solid Tumors Patients | Biotech Hunter | Biotech Hunter